Abstract
We investigated the effect of an emerging biocompatible ionic liquid, choline dihydrogen phosphate (CDHP), on the stability of high-concentration formulations of Herceptin® (trastuzumab). Our results show that CDHP significantly suppresses unfolding and aggregation of trastuzumab, demonstrating great promise as an additive in the development of stable therapeutic antibody formulations.
| Original language | English |
|---|---|
| Pages (from-to) | 10622-10625 |
| Number of pages | 4 |
| Journal | Chemical Communications |
| Volume | 54 |
| Issue number | 75 |
| DOIs | |
| Publication status | Published - 28 Aug 2018 |
Cite this
}
Choline ionic liquid enhances the stability of Herceptin® (trastuzumab). / Reslan, Mouhamad; Ranganathan, Vijayaraghavan; Macfarlane, Douglas R.; Kayser, Veysel.
In: Chemical Communications, Vol. 54, No. 75, 28.08.2018, p. 10622-10625.Research output: Contribution to journal › Article › Research › peer-review
TY - JOUR
T1 - Choline ionic liquid enhances the stability of Herceptin® (trastuzumab)
AU - Reslan, Mouhamad
AU - Ranganathan, Vijayaraghavan
AU - Macfarlane, Douglas R.
AU - Kayser, Veysel
PY - 2018/8/28
Y1 - 2018/8/28
N2 - We investigated the effect of an emerging biocompatible ionic liquid, choline dihydrogen phosphate (CDHP), on the stability of high-concentration formulations of Herceptin® (trastuzumab). Our results show that CDHP significantly suppresses unfolding and aggregation of trastuzumab, demonstrating great promise as an additive in the development of stable therapeutic antibody formulations.
AB - We investigated the effect of an emerging biocompatible ionic liquid, choline dihydrogen phosphate (CDHP), on the stability of high-concentration formulations of Herceptin® (trastuzumab). Our results show that CDHP significantly suppresses unfolding and aggregation of trastuzumab, demonstrating great promise as an additive in the development of stable therapeutic antibody formulations.
UR - http://www.scopus.com/inward/record.url?scp=85053657388&partnerID=8YFLogxK
U2 - 10.1039/c8cc06397d
DO - 10.1039/c8cc06397d
M3 - Article
VL - 54
SP - 10622
EP - 10625
JO - Chemical Communications
JF - Chemical Communications
SN - 1359-7345
IS - 75
ER -